# Efficacy and Safety of JT001 (VV116) Compared With Favipiravir

> **NCT05279235** · PHASE3 · TERMINATED · sponsor: **Shanghai Vinnerna Biosciences Co., Ltd.** · enrollment: 290 (actual)

## Conditions studied

- Moderate to Severe COVID-19

## Interventions

- **DRUG:** JT001
- **DRUG:** JT001 placebo
- **DRUG:** Favipiravir
- **DRUG:** Favipiravir placebo

## Key facts

- **NCT ID:** NCT05279235
- **Lead sponsor:** Shanghai Vinnerna Biosciences Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-03-14
- **Primary completion:** 2022-12-15
- **Final completion:** 2022-12-15
- **Target enrollment:** 290 (ACTUAL)
- **Why stopped:** Development strategy adjustment
- **Last updated:** 2023-02-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05279235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05279235, "Efficacy and Safety of JT001 (VV116) Compared With Favipiravir". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05279235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*